Leucid Bio is a pioneering biotech company developing cell therapies for refractory cancers, especially solid tumors. Leucid was founded to translate 20 years of King's College London (King's) research in the CAR-T field and is led by a highly experienced management team with both scientific and commercial expertise. As part ofLeucid's ongoing relationship with King's, it benefits from exclusive access to and resources from the deep scientific, clinical, and manufacturing expertise of Dr. Maher and his academic team of immuno-oncology experts.

Biotechnology

Leucid Bio

Belinda Carlsen

Arindam Mitra

Caroline Malai Hull

Maya Glover

The Clinical and Research Team at Leucid Bio is dedicated to advancing cell therapies for refractory cancers, focusing on solid tumors. This team manages and conducts clinical trials, oversees clinical operations, and drives innovative research projects. Leveraging extensive scientific expertise and collaboration with King's College London, they ensure effective translation of pioneering CAR-T research into viable therapeutic solutions.

Clinical and Research Team

About

Team members